Status:

TERMINATED

Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma

Lead Sponsor:

Molecular Insight Pharmaceuticals, Inc.

Conditions:

Pheochromocytoma

Paraganglioma

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two disease-specific questionnaires, and to evaluate how effective these questionnaires are at assessing the q...

Eligibility Criteria

Inclusion

  • Provide written informed consent and be willing to comply with protocol requirements
  • Participant is aged ≥ 18
  • Have a documented (medical record) diagnosis of either pheochromocytoma or paraganglioma with active symptoms or within 60 days of curative therapy

Exclusion

  • Patient is currently asymptomatic from pheochromocytoma/paraganglioma diagnosis or duration \> 60 days from curative therapy
  • Participant has a clinically significant disorder, including alcohol or drug abuse, which may interfere with study participation or which may affect the outcome of the study as judged by the investigator.
  • Participant has a mental disability or significant mental illness, legal incapacity or limited legal capacity or any other lack of fitness, in the investigator's opinion, to preclude the subject's participation in or ability to complete the study.
  • Participant is currently too unwell to take part in the study.

Key Trial Info

Start Date :

April 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00911729

Start Date

April 1 2009

Last Update

June 10 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Oxford Outcomes- Nationwide Recruitment within the US

Bethesda, Maryland, United States, 20814

Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma | DecenTrialz